Valuation: NEOVACS

Market Cap 4.09K 4.72K 3.86K 3.5K 6.57K 452K 6.61K 46.09K 17.76K 229K 17.72K 17.33K 729K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -232K -190K -172K -323K -22.23M -325K -2.27M -873K -11.28M -871K -852K -35.86M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 51.4K
-0.94%-5.07%-3.55%+6.11% 45.63B
+0.66%-2.34%+340.62%+530.14% 43.96B
+1.49%-0.78%+41.90%+24.75% 43.73B
+2.11%-1.24%+9.09%+78.25% 40.23B
+0.34%-4.03%+9.34%+38.90% 31.86B
+0.53%-2.08% - - 17.4B
+1.34%+0.70%+21.35%+112.62% 16.62B
+0.83%+2.22%+15.38%+31.47% 14.46B
-1.85%-5.33%+78.63%+31.45% 13.04B
Average +0.36%-1.73%+64.10%+106.71% 29.66B
Weighted average by Cap. +0.64%-2.01%+75.79%+127.41%

Financials

2023 2024
Net sales 533K 616K 503K 457K 857K 59M 863K 6.01M 2.32M 29.93M 2.31M 2.26M 95.16M 434K 501K 410K 372K 697K 48M 702K 4.89M 1.88M 24.35M 1.88M 1.84M 77.41M
Net income -8.74M -10.09M -8.25M -7.49M -14.04M -967M -14.14M -98.54M -37.97M -491M -37.9M -37.06M -1.56B -32.91M -37.99M -31.06M -28.18M -52.86M -3.64B -53.24M -371M -143M -1.85B -143M -140M -5.87B
Net Debt -237K -273K -223K -202K -380K -26.16M -383K -2.67M -1.03M -13.27M -1.03M -1M -42.19M -205K -237K -194K -176K -329K -22.68M -332K -2.31M -891K -11.51M -889K -869K -36.59M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!